Open AccessClinicopathological significance and prognostic value of CD133 expression in triple‐negative breast carcinoma
Author(s) -
Zhao Po,
Lu Yali,
Jiang Xuege,
Li Xiaoying
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.01894.x
Subject(s) - breast cancer , medicine , triple negative breast cancer , immunohistochemistry , stage (stratigraphy) , lymphovascular invasion , oncology , cancer , survival analysis , breast carcinoma , clinical significance , metastasis , log rank test , proportional hazards model , pathology , biology , paleontology
Currently, CD133 is one of the best markers to characterize cancer stem cells and Her‐1 is reported as an important marker for the prognosis of triple‐negative breast cancer. To investigate the relationship between the expression of CD133 and Her‐1 and clinicopathology as well as prognosis in triple‐negative breast cancer, 67 cases of triple‐negative invasive ductal breast carcinoma taken from 422 patients with breast cancer were analyzed by immunohistochemistry and clinicopathology with follow‐up. The CD133 and Her‐1 were expressed as positive in 43.3% (29/67) and 53.7% (36/67) of patients, respectively. The expression of CD133 corresponded to tumor size ( P = 0.022), clinical stage ( P = 0.001) and lymphatic metastasis ( P = 0.001), but not to age and histological grade. By Kaplan–Meier analysis the expression of CD133 was correlative with overall survival (OS) (log rank = 9.346, P = 0.002) and disease free survival (DFS) (log rank = 38.840, P = 0.0001) time of breast cancer patients. The expression of Her‐1 was corresponding to tumor size ( P = 0.031), clinical stage ( P = 0.005) and lymphatic metastasis ( P = 0.002), but not to age and histological grade. By Kaplan–Meier analysis the expression of Her‐1 was correlative with overall survival (OS) (log rank = 7.998, P = 0.005) and DFS (log rank = 4.227, P = 0.040) time of patients with cancer. It is concluded that the expression of CD133 and Her‐1 may be correlative with prognosis in triple‐negative breast cancer. ( Cancer Sci 2011; 102: 1107–1111)